For western blotting, 0.3 million cells were run on a gel (NuPAGE® Novex 4-12% Bis-Tris gel; Invitrogen Corp., Carlsbad, CA, USA) in MOPS running buffer using a commercial protein standard (BenchMark™ Prestained Protein Standard; Invitrogen) as the molecular weight marker.
Calibration of the Chl a peak was performed using a commercial pigment standard from DHI Institute for Water and Environmentt, Denmark).
The assay was calibrated using a commercial nitrite standard (Fluka Analytical TraceCERT).
Fragment analysis was carried out with GeneMapper® 4.0 software (Applied Biosystems, Foster City, USA) using a commercial size standard for allele size assignment (GeneScan ROX 500, Applied Biosystems®).
DNA markers were created by PCR amplification of virulence genes from Escherichia coli generating calculated-sized fragments (bp) of 881, 520, 337, 275 171 and relative sizes confirmed using a commercial DNA size standard (100 bp ladder, Promega).
Using a commercial expression microarray platform and standard filtering criteria, 4,332 unique genes were found to be variably expressed within this set of histologically similar, early-stage ER-positive breast cancers.
DNA from BACs was extracted according to standard protocols using a commercial kit (QIAGEN Plasmid).
Transgenic animals were generated by standard techniques using a commercial provider (mice and more/Hamburg, Germany).
Total nucleic acids were extracted with standard protocols using a commercial platform (Corbett XTractor-Gene, Qiagen, Valencia, CA, USA).
Four hundred-nine serum samples collected from pigs in Lithuania were tested for PCV2-specific IgG to determine the sensitivity and specificity of the newly developed ELISA in parallel using a commercial SERELISA test as a gold standard.
